Journal Article Summary
The article examines the use of long-acting injectable antipsychotics (LAIAs) for treating schizophrenia spectrum disorders (SSD) in children and adolescents. This topic is significant because SSD can have severe impacts on young patients, including cognitive deficits and social impairments, and early intervention is crucial for better outcomes. While LAIAs have been effective in adults, there is limited research on their efficacy and safety in younger populations, making this review essential for understanding their potential role in managing these disorders.
The authors conducted a systematic review of studies published up to March 2022, focusing on original articles and case reports that provided data on the effectiveness and safety of LAIAs in patients aged 18 and younger. Out of 847 articles screened, only 13 met the criteria for inclusion, involving a total of 119 adolescents. The findings indicated that LAIAs were associated with symptom improvement in most cases, with non-adherence to oral medications being a primary reason for initiating LAIA treatment. However, the studies varied in quality, and most reported side effects, with some patients experiencing significant issues like weight gain and extrapyramidal symptoms.
Despite the promising results, the review highlights several limitations, including the lack of randomized controlled trials and the small number of studies available. The authors emphasize that more research is needed to fully understand the safety and efficacy of LAIAs in younger patients. Readers are encouraged to discuss any concerns or questions about LAIA treatment with their healthcare professionals, especially regarding potential side effects and the appropriateness of this treatment for their specific situation.
Medical Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Baeza Inmaculada, Fortea Adriana, Ilzarbe Daniel, Sugranyes Gisela. What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review. Paediatric Drugs 2023. DOI: 10.1007/s40272-023-00558-x. PMID: 36662369. PMCID: PMC9931829.
Featured Pill Pals Product
Risperidone 0.25 mg Tablets --- Generic For Risperdal --- Ajanta
Risperidone 0.25 mg Tablets — Generic For Risperdal — Ajanta is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
